GlassScriptPhysician profile
Carol Alonso
NPI 1386962256
$5,421.87
in general payments reported to CMS, 2019-2025
29 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $174 · 2021: $513 · 2022: $841 · 2023: $1,178 · 2024: $1,311 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.13 |
| Education | $111.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,255.49 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Amgen INC. | $881.97 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $519.47 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $452.01 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $389.84 | 2019-2025 | |
| Galderma Laboratories, L.P. | $358.51 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $271.60 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $205.53 | 2022-2024 | Sotyktu |
| Incyte Corporation | $180.41 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $162.78 | 2019-2025 | Winlevi |
| Janssen Biotech, INC. | $146.36 | 2022-2025 | Tremfya, Remicade, Stelara |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Arcutis Biotherapeutics, INC. | $72.96 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $62.70 | 2019-2022 | |
| Leo Pharma INC. | $39.60 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $37.69 | 2021-2022 | |
| Epi Health, LLC | $36.55 | 2022 | |
| Almirall LLC | $34.13 | 2022-2025 | Klisyri |
| Celgene Corporation | $32.46 | 2019 | |
| Organon LLC | $31.62 | 2025 | |
| Dermira, INC. | $21.61 | 2019 | |
| Genentech USA, INC. | $21.46 | 2019 | |
| Lnhc, INC | $20.56 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $19.70 | 2024 | Vtama |
| Botanix Sb INC | $18.64 | 2025 | Sofdra |
| Biofrontera INC. | $18.13 | 2019 | |
| Journey Medical Corporation | $17.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.